CN109810142A - 一种含氮芥川芎嗪苦参碱衍生物及其制备方法和应用 - Google Patents
一种含氮芥川芎嗪苦参碱衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN109810142A CN109810142A CN201910182300.9A CN201910182300A CN109810142A CN 109810142 A CN109810142 A CN 109810142A CN 201910182300 A CN201910182300 A CN 201910182300A CN 109810142 A CN109810142 A CN 109810142A
- Authority
- CN
- China
- Prior art keywords
- ligustrazine
- mustargen
- mmol
- matrine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FINHMKGKINIASC-UHFFFAOYSA-N tetramethyl-pyrazine Natural products CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 title claims abstract description 29
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical class C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 title claims abstract description 24
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 229940087004 mustargen Drugs 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229930014456 matrine Natural products 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- -1 (2- chloroethyl) amino Chemical group 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- SWVMLNPDTIFDDY-SBSPUUFOSA-N methyl (2r)-2-amino-3-phenylpropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@H](N)CC1=CC=CC=C1 SWVMLNPDTIFDDY-SBSPUUFOSA-N 0.000 description 2
- VEEIFXWJNCAVEQ-RGMNGODLSA-N methyl (2s)-2-amino-3-(1h-imidazol-5-yl)propanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC1=CNC=N1 VEEIFXWJNCAVEQ-RGMNGODLSA-N 0.000 description 2
- VXYFARNRGZWHTJ-FVGYRXGTSA-N methyl (2s)-2-amino-3-(4-hydroxyphenyl)propanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VXYFARNRGZWHTJ-FVGYRXGTSA-N 0.000 description 2
- IYUKFAFDFHZKPI-DFWYDOINSA-N methyl (2s)-2-aminopropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@H](C)N IYUKFAFDFHZKPI-DFWYDOINSA-N 0.000 description 2
- YHYUQHQOUXSXQE-UHFFFAOYSA-N methyl 2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoate Chemical compound COC(=O)C(N)CC1=CC=C(N(CCCl)CCCl)C=C1 YHYUQHQOUXSXQE-UHFFFAOYSA-N 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- JNETYVLEGPSOFY-UHFFFAOYSA-N 3-bromopyrrolidine-2,5-dione Chemical compound BrC1CC(=O)NC1=O JNETYVLEGPSOFY-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical class CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 125000001967 indiganyl group Chemical group [H][In]([H])[*] 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QVDXUKJJGUSGLS-LURJTMIESA-N methyl L-leucinate Chemical compound COC(=O)[C@@H](N)CC(C)C QVDXUKJJGUSGLS-LURJTMIESA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl chloride Substances ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910182300.9A CN109810142B (zh) | 2019-03-12 | 2019-03-12 | 一种含氮芥川芎嗪苦参碱衍生物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910182300.9A CN109810142B (zh) | 2019-03-12 | 2019-03-12 | 一种含氮芥川芎嗪苦参碱衍生物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109810142A true CN109810142A (zh) | 2019-05-28 |
CN109810142B CN109810142B (zh) | 2021-09-14 |
Family
ID=66608667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910182300.9A Active CN109810142B (zh) | 2019-03-12 | 2019-03-12 | 一种含氮芥川芎嗪苦参碱衍生物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109810142B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083666A (zh) * | 2011-10-28 | 2013-05-08 | 北京美迪康信医药科技有限公司 | 一种药物组合物及其制剂和用途 |
CN106854223A (zh) * | 2017-01-05 | 2017-06-16 | 石家庄学院 | 氮芥槲皮素衍生物及其制备方法和用途 |
-
2019
- 2019-03-12 CN CN201910182300.9A patent/CN109810142B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083666A (zh) * | 2011-10-28 | 2013-05-08 | 北京美迪康信医药科技有限公司 | 一种药物组合物及其制剂和用途 |
CN106854223A (zh) * | 2017-01-05 | 2017-06-16 | 石家庄学院 | 氮芥槲皮素衍生物及其制备方法和用途 |
Non-Patent Citations (3)
Title |
---|
宋维良等: "抗肿瘤药物的研究 Ⅲ.含氨基酸的氮芥磷酰胺衍生物的合成", 《药学学报》 * |
崔晓燕等: "苦参碱-氮芥复合物的合成及抗肿瘤活性研究", 《化学试剂》 * |
郑晓辉等: "氮芥型苦参碱衍生物的合成", 《化学试剂》 * |
Also Published As
Publication number | Publication date |
---|---|
CN109810142B (zh) | 2021-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101759683B (zh) | 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 | |
CN107849071A (zh) | 抗病毒的β氨基酸酯膦酰二胺化合物 | |
CN102675403A (zh) | 抗乙肝药物lqc-x的合成及其应用 | |
CN106916177B (zh) | 一种氘代的二肽硼酸或其酯类化合物及其合成方法与用途 | |
CN106866572B (zh) | 一氧化氮供体型β‑榄香烯衍生物及其制备方法和用途 | |
CN106632383A (zh) | 莪术醇衍生物及其制备方法和在抗肿瘤药物中的应用 | |
CN106674242B (zh) | 一种具有抗肿瘤活性的莪术醇衍生物及其制备方法和应用 | |
CN103113386A (zh) | 氮杂环取代二氢青蒿素衍生物及其应用 | |
CN114380864A (zh) | 一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用 | |
CN105153030B (zh) | 全氟基团取代的异喹啉‑1,3(2h,4h)‑二酮及其制法和用途 | |
CN104804000B (zh) | 一种苦参碱类化合物及其制备方法与应用 | |
CN109810142A (zh) | 一种含氮芥川芎嗪苦参碱衍生物及其制备方法和应用 | |
CN105693729B (zh) | 吲哚并 [ 3 , 2 ‑ a ] 咔唑衍生物及其应用 | |
CN107739381A (zh) | 莪术醇衍生物及其在制备抗肿瘤药物中的应用 | |
CN106632374B (zh) | 异甘露糖醇—双苯并咪唑盐类化合物及其制备方法 | |
CN106279322A (zh) | 抗丙肝病毒的核苷类化合物及其应用 | |
CN102212058B (zh) | “单一的复合药”:手性含氮杂环酯、合成法及其在制备低毒性cb1受体抑制剂中的应用 | |
CN105814068B (zh) | 一种取代的氨基磷酸酯类衍生物、其制备方法及其应用 | |
CN106146497A (zh) | 苦参碱肟酯衍生物及其制备方法与应用 | |
CN115677507A (zh) | 氟比洛芬衍生物及其在药物中的应用 | |
CN104926839B (zh) | 具有生物活性的四氢咪唑并噻唑并吡啶盐酸盐类化合物及其制备方法 | |
CN104478892B (zh) | 溴代去甲斑蝥素单酸乙酯及其制备方法和应用 | |
CN107129497A (zh) | 一类含氮芥的槐定碱类衍生物及其制备方法和用途 | |
CN106928224A (zh) | 吲哚类槐定碱衍生物及其制备方法 | |
CN104876893B (zh) | 一类取代高哌嗪氨荒酸铋配合物、配合物的可药用盐以及配合物的制备方法和抗肿瘤应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240313 Address after: Room 701, Unit 1, Building 3, No. 169 Zhufeng Street, Yuhua District, Shijiazhuang City, Hebei Province, 050000 Patentee after: Liu Qingfeng Country or region after: China Address before: 050035 Shijiazhuang college, No.6 Changjiang Avenue, high tech Development Zone, Shijiazhuang City, Hebei Province Patentee before: SHIJIAZHUANG University Country or region before: China |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240517 Address after: Room 301, Building A5, Zhongguancun Overseas Science and Technology Park, No. 568 Cangning Road, High tech Zone, Shijiazhuang City, Hebei Province, 050000 Patentee after: Hebei Hegeshan Biotechnology Co.,Ltd. Country or region after: China Address before: Room 701, Unit 1, Building 3, No. 169 Zhufeng Street, Yuhua District, Shijiazhuang City, Hebei Province, 050000 Patentee before: Liu Qingfeng Country or region before: China |